Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

Core Insights - Annovis Bio Inc. announced new preclinical data showing the synergistic effect of its lead compound, buntanetap, when combined with the GLP-1 agonist dulaglutide in a mouse model of Alzheimer's disease [1][3] Group 1: Company Overview - Annovis Bio Inc. is a late-stage clinical drug platform company focused on developing therapies for neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease [1][7] - The company targets multiple neurotoxic proteins to improve synaptic transmission and reduce neuroinflammation, aiming to reverse neurodegeneration and restore brain function [6][7] Group 2: Research Findings - The combination of buntanetap and dulaglutide restored cognitive function beyond levels seen in healthy controls, with buntanetap alone restoring cognitive function to 100% and dulaglutide to 80% [3] - The recent data presented at the Alzheimer's Association International Conference indicated that another GLP-1 agonist, liraglutide, decreased cognitive decline in Alzheimer's patients by 18% [2] Group 3: Mechanism of Action - GLP-1 agonists, like dulaglutide, have better blood-brain barrier permeability due to their molecular structure, making them suitable for combination therapy with buntanetap [4] - Buntanetap inhibits the formation of neurotoxic proteins, which is crucial for addressing neurodegeneration in Alzheimer's and Parkinson's diseases [6] Group 4: Executive Commentary - The CEO of Annovis Bio expressed excitement over the significant amplification of dulaglutide's effects on memory and learning when combined with buntanetap, highlighting the potential for improved treatment outcomes [5]